51101-11-2

Upstream product

• 719-59-5 5-chloro-2-aminobenzophenone 
• 23864-26-8 6-chloro-2-oxo-4-phenyl-1,2-dihydro-quinoline-3-carbonitrile 

Downstream Products

• 51101-42-9 6-chloro-4-phenyl-2-pyrrolidin-1-yl-quinoline-3-carbonitrile 
• 1433901-74-6 6-chloro-4-phenyl-2-pyrrolidin-1-yl-3-(1H-tetrazol-5-yl)-quinoline 
• 1433901-75-7 6-chloro-4-phenyl-2-piperidin-1-yl-3-(1H-tetrazol-5-yl)-quinoline 
• 1433904-20-1 6-chloro-2-(2-oxo-piperidin-1-yl)-4-phenyl-quinoline-3-carbonitrile 
• 1433903-03-7 6-chloro-4-phenyl-2-piperidin-1-yl-quinoline-3-carbonitrile 

Relevant academic research and scientific papers

Design and synthesis of selective, dual fatty acid binding protein 4 and 5 inhibitors

Dual inhibition of fatty acid binding proteins 4 and 5 (FABP4 and FABP5) is expected to provide beneficial effects on a number of metabolic parameters such as insulin sensitivity and blood glucose levels and should protect against atherosclerosis. Starting from a FABP4 selective focused screening hit, biostructure information was used to modulate the selectivity profile in the desired way and to design potent dual FABP4/5 inhibitors with good selectivity against FABP3. With very good pharmacokinetic properties and no major safety alerts, compound 12 was identified as a suitable tool compound for further in vivo investigations.

NEW ARYL-QUINOLINE DERIVATIVES

The invention provides novel compounds having the general formula (I), wherein R1, R2, R3, R4 R5, R6 and n are as described herein, compositions including the compounds and methods of using the compounds.

ARYL-QUINOLINE DERIVATIVES

The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6 and n are as described herein, compositions including the compounds and methods of using the compounds. The present compounds are useful as fatty-acid binding protein (FABP) 4 and/or 5 inhibitors and may be used for the treatment or prophylaxis of lipodystrophy, type 2 diabetes, dyslipidemia, atherosclerosis, liver diseases involving inflammation, steatosis and/or fibrosis, such as non-alcoholic fatty liver disease, in particular non-alcoholic steatohepatitis, metabolic syndrome, obesity, chronic inflammatory and autoimmune inflammatory diseases.